Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Bristol-Myers investigation page on our website www.glancylaw.com/case/bristol-myers-squibb.
On August 5, 2016, the Company announced that its CheckMate -026 trial investigating the use of Opdivo as monotherapy did not meet its primary endpoint of progression-free survival.
On this news, the Company’s share price fell $12.04, or nearly 16%, to close at $63.28 per share on August 5, 2016, thereby injuring investors.
Then, on October 9, 2016, the Company further disclosed that in patients with ?5% PD-L1 expression, the median progression-free survival was just 4.2 months with Opdivo compared to 5.9 months with platinum-based doublet chemotherapy.
On this news, the Company’s share price fell $5.62, or more than 10%, to close at $49.81 per share on October 10, 2016, thereby further injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Bristol-Myers securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171226005216/en/